CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL

Leukemia Research

Volumn 35, Issue 6, 2011, Pages 750-756

  Majid, Aneela ^a   Lin, Thet Thet ^b   Best, Giles ^c   Fishlock, Keith ^d   Hewamana, Saman ^b   Pratt, Guy ^e   Yallop, Deborah ^d   Buggins, Andrea G S ^d   Wagner, Simon ^a   Kennedy, Ben J ^a   Miall, Fiona ^a   Hills, Robert ^b   Devereux, Stephen ^d   Oscier, David G ^c   Dyer, Martin J S ^a   Fegan, Chris ^b   Pepper, Chris ^b  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

CD49d; CLL; CXCR4; Prognosis

Indexed keywords

ALPHA4 INTEGRIN; CD38 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; FIBRONECTIN; FLUDARABINE; IMMUNOGLOBULIN HEAVY CHAIN; PROTEIN KINASE ZAP 70;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE MARKER; DRUG SENSITIVITY; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIQUID CULTURE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIMARY TUMOR; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD38; ANTINEOPLASTIC AGENTS; CELL SURVIVAL; FLOW CYTOMETRY; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; INTEGRIN ALPHA4; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MIDDLE AGED; MULTIVARIATE ANALYSIS; MUTATION; PROGNOSIS; RECEPTORS, CXCR4; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; VIDARABINE; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 79955601718     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.10.022     Document Type: Article

References (33)

1. Rai K.R., Sawitsky A., Cronkite E.P., Chanana A.D., Levy R.N., Pasternack B.S. Clinical staging of chronic lymphocytic leukemia. Blood 1975, 46:219-234.
2. Hamblin T.J., Davis Z., Gardiner A., Oscier D.G., Stevenson F.K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999, 94:1848-1854.
3. Damle R.N., Wasil T., Fais F., et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999, 94:1840-1847.
4. Wiestner A., Rosenwald A., Barry T.S., et al. ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile. Blood 2003, 101:4944-4951.
5. Davis B.H., Schwartz M. ZAP-70 expression is low in normal precursor B cells or hematogones. Cytometry B Clin Cytom 2006, 70:315-319.
6. Matrai Z., Lin K., Dennis M., et al. CD38 expression and Ig VH gene mutation in B-cell chronic lymphocytic leukemia. Blood 2001, 97:1902-1903.
7. Hamblin T.J., Orchard J.A., Ibbotson R.E., et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002, 99:1023-1029.
8. Krober A., Seiler T., Benner A., et al. V(H) mutation status CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood 2002, 100:1410-1416.
9. Crespo M., Bosch F., Villamor N., et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003, 348:1764-1775.
10. Kim S.Z., Chow K.U., Kukoc-Zivojnov N., et al. Expression of ZAP-70 protein correlates with disease stage in chronic lymphocytic leukemia and is associated with, but not generally restricted to, non-mutated Ig VH status. Leuk Lymphoma 2004, 45:2037-2045.
11. Gattei V., Bulian P., Del Principe M.I., et al. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood 2008, 111:865-873.
12. Shanafelt T.D., Geyer S.M., Bone N.D., et al. CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. Br J Haematol 2008, 140:537-546.
13. Nuckel H., Switala M., Collins C.H., et al. High CD49d protein and mRNA expression predicts poor outcome in chronic lymphocytic leukemia. Clin Immunol 2009, 131:472-480.
14. Eksioglu-Demiralp E., Alpdogan O., Aktan M., et al. Variable expression of CD49d antigen in B cell chronic lymphocytic leukemia is related to disease stages. Leukemia 1996, 10:1331-1339.
15. Rose D.M., Han J., Ginsberg M.H. Alpha4 integrins and the immune response. Immunol Rev 2002, 186:118-124.
16. Koopman G., Keehnen R.M., Lindhout E., et al. Adhesion through the LFA-1 (CD11a/CD18)-ICAM-1 (CD54) and the VLA-4 (CD49d)-VCAM-1 (CD106) pathways prevents apoptosis of germinal center B cells. J Immunol 1994, 152:3760-3767.
17. Hayashida K., Shimaoka Y., Ochi T., Lipsky P.E. Rheumatoid arthritis synovial stromal cells inhibit apoptosis and up-regulate Bcl-xL expression by B cells in a CD49/CD29-CD106-dependent mechanism. J Immunol 2000, 164:1110-1116.
18. de la Fuente M.T., Casanova B., Garcia-Gila M., Silva A., Garcia-Pardo A. Fibronectin interaction with alpha4beta1 integrin prevents apoptosis in B cell chronic lymphocytic leukemia: correlation with Bcl-2 and Bax. Leukemia 1999, 13:266-274.
19. de la Fuente M.T., Casanova B., Moyano J.V., et al. Engagement of alpha4beta1 integrin by fibronectin induces in vitro resistance of B chronic lymphocytic leukemia cells to fludarabine. J Leukoc Biol 2002, 71:495-502.
20. Pittner B.T., Shanafelt T.D., Kay N.E., Jelinek D.F. CD38 expression levels in chronic lymphocytic leukemia B cells are associated with activation marker expression and differential responses to interferon stimulation. Leukemia 2005, 19:2264-2272.
21. Zucchetto A., Benedetti D., Tripodo C., et al. CD38/CD31, the CCL3 and CCL4 chemokines, and CD49d/vascular cell adhesion molecule-1 are interchained by sequential events sustaining chronic lymphocytic leukemia cell survival. Cancer Res 2009, 69:4001-4009.
22. Lenz G., Wright G., Dave S.S., et al. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med 2008, 359:2313-2323.
23. Burger J.A., Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 2009, 23:43-52.
24. Kurtova A.V., Tamayo A.T., Ford R.J., Burger J.A. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood 2009, 113:4604-4613.
25. van Dongen J.J., Langerak A.W., Bruggemann M., et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003, 17:2257-2317.
26. Zucchetto A., Bomben R., Dal Bo M., et al. CD49d in B-cell chronic lymphocytic leukemia: correlated expression with CD38 and prognostic relevance. Leukemia 2006, 20:523-525. author reply 528-9.
27. Rossi D., Zucchetto A., Rossi F.M., et al. CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia. Haematologica 2008, 93:1575-1579.
28. Buchner M., Baer C., Prinz G., et al. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood 2010, 115:4497-4506.
29. Burger J.A., Kipps T.J. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. Blood 2006, 107:1761-1767.
30. Burger J.A., Burkle A. The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target. Br J Haematol 2007, 137:288-296.
31. Barretina J., Juncà J., Llano A., et al. CXCR4 and SDF-1 expression in B-cell chronic lymphocytic leukemia and stage of the disease. Ann Hematol 2003, 82:500-505.
32. Ferrajoli A., Lee B.N., Schlette E.J., et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008, 111:5291-5297.
33. Calandra G., Bridger G., Fricker S. CXCR4 in clinical hematology. Curr Top Microbiol Immunol 2010, April 14 [Epub ahead of print] PMID: 20397073.